Posted on 11/28/2025 9:50:18 PM PST by Red Badger
A new version of Ozempic is in the works for next year and is subject to FDA approval
The manufacturers of Ozempic and Mounjaro are planning to launch a new weight loss method in 2026.
While Ozempic remains a GLP-1 medicine for adults with Type-2 diabetes, and not a weight loss drug, Mounjaro - the brand name for tirzepatide - can be prescribed for weight-loss via the NHS.
These drugs typically come in jab form, but it appears the new era of medicine could be upon us fairly soon.
Mounjaro's manufacturer, Eli Lilly, announced in September that it was hoping to 'offer a convenient, once-daily pill that can be scaled globally'.
Named 'Orforglipron', it can be 'taken once per day without food and water restrictions'.
While it remains in development, initial tests showed that it 'lowered weight by an average of 10.5 per cent (22.9 lbs) compared to 2.2 per cent (5.1 lbs) with a placebo', Eli Lilly explained.
Kenneth Custer, executive vice president at Eli Lilly, added: "With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting."
It comes after Eli Lilly said that its experimental pill, orforglipron, outperformed Novo Nordisk’s oral semaglutide in a year-long trial.
At the highest dose, orforglipron delivered greater weight loss - an average 9.2 percent (about 19.7lbs) compared with Ozempic's 5.3 percent (about 11 lbs).
When including all participants, Lilly’s pill produced 8.2 percent weight loss versus 5.3 percent for semaglutide.
“For the majority of patients, this could be the main medicine that they need to control their Type 2 diabetes as well as their obesity,” Eli Lilly Chief Scientific Officer Dan Skovronsky
Ozempic.
Drugmakers had hoped the oral version of the drug may have had a new use in the form of slowing down the progression of Alzheimer’s - however, it was reported that an oral version failed to do so in two major trials.
The Danish drugmaker said patients taking the pill saw no meaningful reduction in disease advancement, which put a hold on expectations that the bestselling diabetes medication might have a new use.
As many companies are rushing to bring an anti-obesity pill to market, it seems there would be demand for it, particularly for people who don't like needles.
“With this newer generation of medications, we’re not just focusing on weight loss,” David Lau, an endocrinologist and professor emeritus at the University of Calgary Cumming School of Medicine told The Washington Post.
“We’re talking about changes beyond what you see on the scale.”
Despite all the optimism, the drugs are still subject to FDA approval.
LADbible Group has contacted Novo Nordisk and Eli Lilly for comment.
Dear FRiends,
We need your continuing support to keep FR funded. Your donations are our sole source of funding. No sugar daddies, no advertisers, no paid memberships, no commercial sales, no gimmicks, no tax subsidies. No spam, no pop-ups, no ad trackers.
If you enjoy using FR and agree it's a worthwhile endeavor, please consider making a contribution today:
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you,
Jim
.....there is a drug advertised for some condition
which has a side effect of having your limbs fall off ...
Why in God’s name are these harmful drugs even put on the market?
Insane.
I am type 2 diabetes also. My whole life i have been thin. Six foot one inch most often a 32 inch waist. Most i have ever weighed was one hundred ninety at retirement. I dropped fifty pounds after i retired. Wasn’t trying to. They’ve been testing me for this and that. Finding nothing.
Weight loss is also a Type 2 symptom from what I’ve read! Best wishes to you!
Yes, for some, it is for me.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.